Nicolaos J. Palaskas, MD, PhD

Nicolaos J. Palaskas, MD, PhD

Assistant Professor, Department of Medicine, Hematology/Oncology





Glioblastoma metabolism and epigenetics, Memorial Sloan-Kettering Cancer Center Human Oncology and Pathogenesis Program, New York, NY, 2012
Hematology/Oncology, UCLA School of Medicine, Los Angeles, CA, 2012 - 2015


Internal Medicine, St. Elizabeth's Medical Center, 2009


PhD, UCLA, Molecular, Cellular, and Integrative Physiology, Los Angeles, CA, 2017
MD, Aristotle University of Thessaloniki, Thessaloniki, Macedonia, 2004


Internal Medicine, St Elizabeth’s Medical Center, Boston, MA, 2009 - 2011

Contact Information

Scientific Interests

Dr. Nicolaos J. Palaskas' primary interest is in tumor metabolism, with particular focus on the intersection of iron and phospholipid metabolism. Deregulation of iron and phospholipids leads to ferroptosis, a newly discovered form of cell death resulting from cell membrane damage. He is interested in understanding how external cues interact with the genetic makeup of cells to shape membrane lipid composition and how this affects targeting by the immune system and sensitivity to ferroptosis-inducing agents and other therapeutics.

Highlighted Publications

Kostaras, E., Kaserer, T., Lazaro, G., Heuss, S. F., Hussain, A., Casado, P., Hayes, A., Yandim, C., Palaskas, N., Yu, Y., Schwartz, B., Raynaud, F., Chung, Y.-L., Cutillas, P. R., & Vivanco, I. (2020). A systematic molecular and pharmacologic evaluation of AKT inhibitors reveals new insight into their biological activity. British Journal of Cancer.

Palaskas, N. J., Garcia, J. D., Shirazi, R., Shin, D. S., Puig-Saus, C., Braas, D., Ribas, A., & Graeber, T. G. (2019). Global alteration of T-lymphocyte metabolism by PD-L1 checkpoint involves a block of de novo nucleoside phosphate synthesis. Cell Discovery, 5, 62.

Shin, D. S., Zaretsky, J. M., Escuin-Ordinas, H., Garcia-Diaz, A., Hu-Lieskovan, S., Kalbasi, A., Grasso, C. S., Hugo, W., Sandoval, S., Torrejon, D. Y., Palaskas, N., Rodriguez, G. A., Parisi, G., Azhdam, A., Chmielowski, B., Cherry, G., Seja, E., Berent-Maoz, B., Shintaku, I. P., … Ribas, A. (2017). Primary Resistance to PD-1 Blockade Mediated by JAK1/2 Mutations. Cancer Discovery, 7(2), 188–201.

Tsoi, J., Robert, L., Paraiso, K., Galvan, C., Sheu, K. M., Lay, J., Wong, D. J. L., Atefi, M., Shirazi, R., Wang, X., Braas, D., Grasso, C. S., Palaskas, N., Ribas, A., & Graeber, T. G. (2018). Multi-stage Differentiation Defines Melanoma Subtypes with Differential Vulnerability to Drug-Induced Iron-Dependent Oxidative Stress. Cancer Cell.

Grommes, C., Pastore, A., Palaskas, N., Tang, S. S., Campos, C., Schartz, D., Codega, P., Nichol, D., Clark, O., Hsieh, W.-Y., Rohle, D., Rosenblum, M., Viale, A., Tabar, V. S., Brennan, C. W., Gavrilovic, I. T., Kaley, T. J., Nolan, C. P., Omuro, A., … Mellinghoff, I. K. (2017). Ibrutinib Unmasks Critical Role of Bruton Tyrosine Kinase in Primary CNS Lymphoma. Cancer Discovery, 7(9), 1018–1029.